Actofin Tablet (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Youngpoong Pharmaceutical Co., Ltd.
MFDS item code 201603241 · Approved 2016.06.07
Improves blood glucose control in type 2 diabetes mellitus
This medication is used to help control blood sugar in patients with Type 2 Diabetes. It can be administered alone while following dietary and exercise regimens, and in cases where other oral hypoglycemic agents have not been effective, it may be used in combination with sulfonylureas, metformin, or insulin. Additionally, it is important for patients with Type 2 Diabetes to also engage in nutritional counseling and, if necessary, weight loss and regular physical activity. These treatment efforts are very helpful not only for initial treatment but also for maintaining the drug's effectiveness. Therefore, this medication is used as an effective treatment to improve blood sugar control.
This medicine is administered orally once daily, regardless of meals. Diabetes management should be individualized for each patient. Ideally, response to treatment should be evaluated by measuring glycated hemoglobin (HbA1c), which is a more accurate diagnostic method than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the preceding 2~3 months. Clinically, this medicine should be administered for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin, unless glycemic control in the patient with diabetes worsens. 1. Monotherapy This medicine may be started at 15 mg of pioglitazone once daily as monotherapy in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered concomitantly with a sulfonylurea. The initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered concomitantly with metformin. The initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered concomitantly with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when combination therapy with this medicine is initiated. However, if a patient receiving this medicine concomitantly with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Further dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal insufficiency (see General Precautions, Patients with Renal Impairment). Do not initiate treatment with this medicine if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT) at the start of treatment (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. No data are available on the use of this medicine in combination with other thiazolidinediones.
Use is not recommended in children under 18 years of age because there is no experience with its use in this age group.
This medication is used to treat Type 2 Diabetes and works with insulin to help regulate blood sugar levels. When taking this medication, heart failure may develop or worsen; therefore, if symptoms such as sudden weight gain, shortness of breath, or swelling occur, it is vital to inform healthcare professionals immediately. Patients with heart failure should not use this medication, and caution should be exercised for patients at high risk of heart failure. This medication may cause fluid retention leading to swelling; thus, it is essential to consult healthcare professionals if swelling symptoms appear. Patients with a history of bladder cancer or current active bladder cancer should not take this medication, and if gross hematuria or urinary disorders occur, they must inform their doctor immediately. Liver function may be affected, so regular liver function tests should be performed before and during treatment, and any symptoms of liver dysfunction should be reported to healthcare professionals immediately. Using this medication with other hypoglycemic agents may increase the risk of hypoglycemia; therefore, understanding the symptoms of hypoglycemia and how to respond is essential, and dosage adjustments of other medications may be necessary. Women who are pregnant or may become pregnant should consult their doctor before taking this medication, and premenopausal women may need to use appropriate contraceptive methods due to the increased risk of pregnancy while taking this medication. Elderly patients or those with impaired renal or liver function should use this medication with greater care and should follow the instructions of their healthcare provider. Additionally, this medication may not exhibit special symptoms in the case of overdose, but if an overdose is suspected, immediate notification to healthcare professionals and appropriate treatment is required. This medication has not been confirmed for safety and efficacy in children, so it is not used in this population. Finally, this medication should be stored in a designated container and kept out of reach of children, and it should be taken once daily; if a dose is missed, one must be careful not to take double the dose the next day.
Congestive heart failure, excessive and rapid weight changes, shortness of breath, swelling, fluid retention, inadequate blood sugar control, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular predisposition, hospitalization due to worsening congestive heart failure, emergency room visits due to congestive heart failure, decreased vision, diabetic macular edema, fatal and non-fatal liver failure, increased liver enzymes, worsening liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, chest pain, fatigue, weakness, dyspepsia, nausea, itching, chest discomfort, tremors, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, numbness, muscle rigidity, discomfort in the head, loss of appetite, constipation, increased blood sugar, dizziness, decreased appetite, discomfort in the right upper abdomen, black urine, jaundice, weight gain
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage will ensure the medication retains its effectiveness.
White to grayish-white, convex cylindrical tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Youngpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.